| TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy Z Grada, M Hegde, T Byrd, DR Shaffer, A Ghazi, VS Brawley, A Corder, ... Molecular Therapy-Nucleic Acids 2, 2013 | 512 | 2013 |
| HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors N Ahmed, VS Salsman, Y Kew, D Shaffer, S Powell, YJ Zhang, ... Clinical cancer research 16 (2), 474-485, 2010 | 401 | 2010 |
| Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma S Kakarla, KKH Chow, M Mata, DR Shaffer, XT Song, MF Wu, H Liu, ... Molecular Therapy 21 (8), 1611-1620, 2013 | 326 | 2013 |
| T cells redirected to EphA2 for the immunotherapy of glioblastoma KKH Chow, S Naik, S Kakarla, VS Brawley, DR Shaffer, Z Yi, N Rainusso, ... Molecular Therapy 21 (3), 629-637, 2013 | 269 | 2013 |
| In vivo discovery of immunotherapy targets in the tumour microenvironment P Zhou, DR Shaffer, DA Alvarez Arias, Y Nakazaki, W Pos, AJ Torres, ... Nature 506 (7486), 52-57, 2014 | 253 | 2014 |
| T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies DR Shaffer, B Savoldo, Z Yi, KKH Chow, S Kakarla, DM Spencer, G Dotti, ... Blood, The Journal of the American Society of Hematology 117 (16), 4304-4314, 2011 | 183 | 2011 |
| Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes N Ahmed, Z Grada, M Hedge, M Baker, DR Shaffer US Patent App. 13/788,267, 2013 | 116 | 2013 |
| Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma A Ghazi, A Ashoori, PJ Hanley, VS Brawley, DR Shaffer, Y Kew, ... Journal of immunotherapy 35 (2), 159-168, 2012 | 84 | 2012 |
| IAPAC guidelines for optimizing the HIV care continuum for adults and adolescents International Advisory Panel on HIV Care Continuum Optimization Journal of the International Association of Providers of AIDS Care (JIAPAC …, 2015 | 77 | 2015 |
| Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein–Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation PJ Hanley, DR Shaffer, CRY Cruz, S Ku, B Tzou, H Liu, ... Cytotherapy 13 (8), 976-986, 2011 | 63 | 2011 |
| Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytes AS Kaka, DR Shaffer, R Hartmeier, AM Leen, A Lu, A Bear, CM Rooney, ... Journal of immunotherapy 32 (7), 726-736, 2009 | 51 | 2009 |
| Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies SMG Gottschalk, DR Shaffer, DM Spencer US Patent App. 13/881,772, 2013 | 42 | 2013 |
| Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment VS Salsman, KKH Chow, DR Shaffer, H Kadikoy, XN Li, C Gerken, ... PloS one 6 (5), e20267, 2011 | 42 | 2011 |
| Immunotherapeutic options for Epstein–Barr virus-associated lymphoproliferative disease following transplantation DR Shaffer, CM Rooney, S Gottschalk Immunotherapy 2 (5), 663-671, 2010 | 19 | 2010 |
| Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 … JD Weaver, EC Stack, JA Buggé, C Hu, L McGrath, A Mueller, M Wong, ... Oncoimmunology 11 (1), 2141007, 2022 | 15 | 2022 |
| Foreign or domestic CARs: Receptor ligands as antigen-binding domains DR Shaffer, P Zhou, S Gottschalk Medical Sciences 2 (1), 23-36, 2014 | 10 | 2014 |
| Preclinical evaluation of JTX-1811, an anti-CCR8 antibody with enhanced ADCC activity, for preferential depletion of tumor-infiltrating regulatory T cells F Dépis, C Hu, J Weaver, L McGrath, B Klebanov, J Buggé, B Umiker, ... Cancer Research 80 (16_Supplement), 4532-4532, 2020 | 9 | 2020 |
| Chemotherapy-resistant immune cells KKH Chow, Z Yi, DR Shaffer, SMG Gottschalk US Patent App. 14/773,416, 2016 | 8 | 2016 |
| Inhibition of LILRB2 by a novel blocking antibody designed to reprogram immunosuppressive macrophages to drive T-cell activation in tumors B Umiker, Y Hashambhoy-Ramsay, J Smith, T Rahman, A Mueller, ... Molecular Cancer Therapeutics 22 (4), 471-484, 2023 | 7 | 2023 |
| Methods and compositions for reducing immunosupression by tumor cells KW Wucherpfennig, G Dranoff, P Zhou, D Shaffer, N Hacohen, HI Cantor, ... US Patent 9,944,931, 2018 | 7 | 2018 |
